Evotec Receives Milestone Payment from Boehringer Ingelheim
News Jul 30, 2009
Evotec AG has announced that a further research milestone, leading to payments to Evotec, has been successfully achieved in its drug discovery collaboration with Boehringer Ingelheim.
The milestone was achieved for the identification and selection of a second compound to be advanced into preclinical development within an existing program. This represents the sixth milestone achieved in this multi-year, multi-target collaboration and is the second compound selected for pre-development in the last twelve months.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “It is great to see the scientific progress that top-class discovery alliance projects can bring. We are jointly progressing several projects with Boehringer Ingelheim at this stage, so we are optimistic to see further product progress soon.”